| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 4, 2013Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for Superior Hemostasis and Reinforced Coil for Proven Kink Resistance
MINNEAPOLIS -- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT)...
-
Apr 2, 2013Medtronic Announces FDA Clearance and First Uses of New Oxygenation System for Adult Cardiac SurgeryNew System Designed for Patient Safety, Ease of Use During Open-Heart Procedures
MINNEAPOLIS - April 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion®...
-
Mar 19, 2013
MINNEAPOLIS -- March 19, 2013 -- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $1.0 billion of its 1.375% Senior Notes due 2018, $1.25 billion of its 2.750% Senior Notes due...
-
Mar 11, 2013ACC.13 Presentation Features Unprecedented Data on Nearly 5,000 Patients, Including "All Comers," from Global RESOLUTE Clinical Program
SAN FRANCISCO -- March 11, 2013 -- Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as...
-
Mar 10, 201324-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology
MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...